Why do only approximately 40-50% of Wilson Disease (WD) patients develop neurological symptoms (tremor, dystonia, dysarthria, choreoathetosis) while the remainder present with hepatic-only disease? What determines neurological involvement and treatment response?
This addresses a critical gap in understanding WD pathogenesis: the mechanism of selective neuronal vulnerability and why copper chelation reverses hepatic but not always neurological symptoms.
Wilson disease is caused by ATP7B gene mutations leading to impaired copper excretion into bile and incorporation into ceruloplasmin. This results in copper accumulation in liver, brain (especially basal ganglia), and cornea. However, the mechanism determining which patients develop neurological symptoms versus hepatic-only disease remains unknown. Additionally, neurological symptoms often persist even after successful chelation therapy.
Genome-wide association study to identify variants modifying neurological vs hepatic phenotype.
Prospective study to identify predictors of neurological treatment response.
| Parameter | Specification |
|---|---|
| Population | 100 newly diagnosed neurological WD patients |
| Intervention | Standard chelation therapy (penicillamine or trientine) |
| Duration | 2 years |
| Outcomes | Neurological symptom improvement (King's Score), MRI changes |
| Measure | Target |
|---|---|
| Genetic modifier identification | OR >2.0, p < 0.001 |
| Treatment response prediction AUC | >0.80 |
| Biomarker correlation with outcome | r > 0.6 |
| Resource | Estimated Cost |
|---|---|
| WGS/cohort | $300,000 |
| Biomarker assays | $150,000 |
| MRI assessments | $200,000 |
| Clinical coordination | $250,000 |
| Total | $900,000 |
Score: 7/10
Score: 8/10
Score: 8/10
Score: 71/140 | SV:7 F:8 N:8 DI:8 R:7 CE:7 TE:7 EB:7 AU:7 TP:8